USING ACYCLOVIR TO PREVENT UVB LIGHT REACTIVATION OF HERPES SIMPLEX

使用阿昔洛韦预防单纯疱疹病毒的 UVB 光再激活

• 批准号: 3978347
• 负责人: R CORSEY
• 金额: --
• 依托单位: DIVISION OF RESEARCH SERVICES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3978347
• 关键词: Herpesviridae disease; acyclovir; analgesics; chemotherapy; communicable disease control; drug administration routes; drug metabolism; herpes simplex virus 1; human subject; radiation dosage; radiobiology; relapse /recurrence; ultraviolet radiation; wound healing

Ultraviolet light (UVB) has been demonstrated to induce reactivation of Herpes Simplex Virus in non-genital areas in which prior recurrences had been observed. The purpose of this study is to evaluate the ability of acyclovir to suppress the induction of recurrent Herpes Simplex Virus infection by UVB light. Patients will be randomized on a cycle of radiation to receive oral acyclovir or placebo pills for six days in a double-blind study. Each cycle will consist of four challenge irradiations with four miminal erythematous doses of UVB light each. Each patient will be followed for documentation of recurrent lesions induced by UVB light or spontaneously occuring lesions throughout the course of the study. Acyclovir has been shown to have significant effects on pain, lesion crusting, lesion healing and viral sheading when administered intravenously. It has also been shown to have significant efficacy in relief of pain, itching and viral sheading time when topically administered. Oral as opposed to intravenous or topical acyclovir will be used exclusively in this study. An area of skin which is near but not overlapping sites previously involved with herpetic recurrence will be selected. A template will be utilized to isolate four 1 cm in diameter areas of skin. A special apparatus which can hold four fluorescent tubes at a distance of 25.4 cm from the target site will be utilized. The fluorescent tubes will have output primarily of UVB (290-320 nm) with a reduced output of UVA (320-400 nm) average caucasian skin pigmentation would call for about four minutes exposure with increased melanin requiring more exposure time.

紫外线 (UVB) 已被证明可以诱导重新激活 先前复发过的非生殖器区域的单纯疱疹病毒 被观察到。 本研究的目的是评估以下人员的能力 阿昔洛韦抑制单纯疱疹病毒复发的诱导 UVB 光感染。 患者将被随机分为一个周期 接受口服阿昔洛韦或安慰剂药丸六天的放射治疗 双盲研究。 每个周期将包含四次挑战照射 每次使用四次最小红斑剂量的 UVB 光。 每个患者都会 跟踪记录由 UVB 光引起的复发性病变或 在整个研究过程中自发发生的损伤。 阿昔洛韦已被证明对疼痛、病变有显着效果 给药后结痂、病变愈合和病毒脱落 静脉注射。 它还被证明在以下方面具有显着功效： 局部使用时可缓解疼痛、瘙痒和病毒脱落时间 管理。 口服阿昔洛韦而不是静脉注射或局部阿昔洛韦 专门用于本研究。 接近但不存在的皮肤区域 先前与疱疹复发有关的重叠部位将被 已选择。 将使用模板来隔离四个直径为 1 厘米的 皮肤区域。 一种可容纳四根荧光灯管的特殊装置 将使用距目标地点 25.4 厘米的距离。 这 荧光灯管的输出主要为 UVB（290-320 nm）， UVA（320-400 nm）输出减少，白种人皮肤平均色素沉着 随着黑色素的增加，需要暴露约四分钟 更多的曝光时间。